David Goldberg
University of Miami, FL·Medicine & Clinical Research
Alcohol-associated liver disease (ALD) is now the leading reason people in the U.S. receive liver transplants.
- Fields
Medicine & Clinical Research
Public Health & Epidemiology
- Topics
alcohol-associated liver disease
alcoholic hepatitis
alcohol-associated hepatitis
- Grants
- 1 known grant, through Jul 2030
What they work on
- Develop risk prediction models for transplant-free survival among patients with alcohol-associated liver disease who have limited access to transplant, to identify those most in need of early liver transplant referral.
- Evaluate barriers and facilitators to referral for early liver transplant in alcohol-associated liver disease across the INTEGRATE transplant centers.
- Apply causal inference methods to observational data to identify biopsychosocial factors that cause or predict outcomes at key time points after early transplant.
- Define stakeholder perceptions and preferences for selection and outcomes, and evaluate how integrated alcohol use disorder and liver care influences outcomes after early liver transplant.
More about the research
ALD includes alcohol-associated cirrhosis (scarring of the liver) and alcohol-associated hepatitis (sudden severe liver inflammation). Transplant centers have traditionally required six months without alcohol before evaluation. Looking back at past cases suggests that early liver transplant (eLT), evaluation with less than six months of abstinence, can give acceptable results. But there is little data that follows patients forward across several centers or captures their biological, psychological and social situation. Stopping drinking is the biggest factor in survival. Care that combines treatment for alcohol use disorder with liver care may help, but its effect on outcomes after transplant has not been studied systematically.
Why it matters
Patients with severe alcohol-associated liver disease face a high risk of death, and decisions about who receives early transplant rest on limited data. Clearer evidence on referral barriers, outcome predictors and integrated addiction-and-liver care could help transplant teams select patients more fairly. It could also help them support recovery after transplant and improve outcomes that patients and families value.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Norah Terrault
University of Southern California, CA·Medicine & Clinical Research
Examine how centers select patients with severe alcohol-associated liver disease for early liver transplantation, using selection-meeting recordings, checklists and clinician interviews to find sources of bias and unequal access.
Katie Ross-Driscoll
Indiana University-Purdue University-Indianapolis, IN·Public Health & Epidemiology·Early-career
Identify patient, social and geographic factors linked to referral for liver transplant among patients with end-stage liver disease, using data from two transplant centers serving 108 counties across Georgia, Alabama, Tennessee and South Carolina.
Bernd Schnabl
University of California-San Diego, CA·Medicine & Clinical Research
Test whether the sugar-adding enzyme Fucosyltransferase 2 (Fut2) on intestinal lining cells limits colonization and translocation of the gut bacterium Enterococcus faecalis and thereby reduces liver disease, using mouse models of ethanol feeding.
The school
University of Miami: 30 labs on PI Pages, $559M a year on research, 297 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.